title: [Detection of laboratory biomarkes in haematological and pulmonology patients at high risk for aspergillosis].
abstract: BACKGROUND
  During the past decades a dramatic increase in the incidence of invasive fungal diseases, especially invasive aspergillosis has been observed. Undiagnosed and diagnosed late invasive aspergillosis is followed by lethality of up to 90%. Detection of early laboratory biomarkers (galactomannan and anti-Aspergillus antibodies) contributes to early diagnosis and is used for screening, as well as for monitoring therapy of aspergillosis.
  
  
  OBJECTIVE
  The aim was to evaluate usefulness of "non-culture" methods (galactomannan and anti-Aspergillus antibodies IgA, IgM and IgG) for early diagnosis of aspergillosis in high-risk patients.
  
  
  METHODS
  Prospective two-year study involved 262 high-risk patients for aspergillosis. In pulmonology and haematology patients (adults and children) blood samples were tested on galactomannan and anti-Aspergillus antibodies.
  
  
  RESULTS
  Early laboratory biomarkers were statistically significantly higher in pulmonology patients (p = 0.00033). However, in haematological patients galactomannan was a more frequently positive finding, while in pulmonology patients it was the finding of anti-Aspergillus antibodies. It is interesting that, despite the possible immunosuppression, in about 1/3 of haematological patients anti-Aspergillus antibodies were confirmed.
  
  
  CONCLUSIONS
  Early diagnosis and treatment of aspergillosis represent both clinical and laboratory problem. Nowadays, the application of new "non-culture" methods is of particular importance for the outcome of aspergillosis. Clinical features, laboratory findings of biomarkers and their correct interpretation significantly increase the possibility of timely implementation of appropriate therapy. In this regard, the new organization of reference laboratory for medical mycology has significantly improved the outcome of aspergillosis in high-risk patients in our country. However, further investigations, implementation of European standards and introduction of new diagnostic methods are necessary in this field.
authors: Eleonora
authors: E
authors: Ratkov
authors: Ana
authors: A
authors: Vidović
authors: Predrag
authors: P
authors: Minić
authors: Dragana
authors: D
authors: Janić
authors: Sandra
authors: S
authors: Šipetić-Grujičić
authors: Aleksandar
authors: A
authors: Džamić
authors: Valentina
authors: V
authors: Arsić-Arsenijević
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000908:Antibodies, Fungal / Q000032:analysis* / Q000097:blood; D001230:Aspergillus / Q000276:immunology* / Q000302:isolation & purification; D002648:Child; D002675:Child, Preschool; D042241:Early Diagnosis; D005260:Female; D005690:Galactose / Q000031:analogs & derivatives; D006402:Hematologic Diseases / Q000276:immunology / Q000382:microbiology*; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D008171:Lung Diseases / Q000276:immunology / Q000382:microbiology*; D008297:Male; D008351:Mannans / Q000032:analysis*; D008875:Middle Aged; D009894:Opportunistic Infections / Q000175:diagnosis*; D055732:Pulmonary Aspergillosis / Q000175:diagnosis*; D012307:Risk Factors; D055815:Young Adult
chemical_list: D000908:Antibodies, Fungal; D008351:Mannans; C012990:galactomannan; D005690:Galactose